Drug Trial Radar · NCT07016802
A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD)
Last checked: Nov 20, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Jun 9, 2025
Primary completion
Nov 25, 2026
Study completion Nov 25, 2026
Sponsor
- Lead sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To check how safe and well-tolerated a single subcutaneous injection of GenSc134 is in healthy male volunteers, a multiple-doses subcutaneous injection of GenSc134 is in healthy volunteers,a single subcutaneous injection of GenSc134 is in AGHD patients.
Conditions
- Safety
- Tolerability
- Adult Growth Hormone Deficiency
Interventions
GenSci134Drug
only one dose of GenSci134 to be given, subcutaneous , 7 dose level groups will be assigned.
PlaceboDrug
only one dose of GenSci134 Placebo to be given, subcutaneous , 7 dose level groups will be assigned.
Recombinant Human Growth Hormone Injection (Norditropin®)Drug
A single dose of 0.2 mg/day, administered once daily (QD) for 28 consecutive days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events and serious adverse eventsTime frame: From Day 0 to Month 3
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.